2,914 material Form 8-K filings that 2,352 companies we cover made with the SEC in August 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Cosmos Health reported second-quarter 2026 revenue of $18.99 million, up 28.8% from a year earlier, and said it was the highest second-quarter revenue in its history. The net loss widened to $6.09 million from $2.83 million, which the company attributed mainly to $2.65 million of non-cash charges, chiefly fair value adjustments on its financing arrangements.
Q2 2026 revenue was $18.99 million, up 28.8% from $14.75 million; first-half revenue was $36.91 million, up 29.7%.
Q2 2026 net loss was $6.09 million, compared with $2.83 million in Q2 2025; first-half net loss was $8.89 million versus $3.65 million.
Q2 2026 gross profit was $1.51 million, up 29.9%; excluding $0.33 million of sales discount reversals, adjusted gross profit was $1.84 million, up 58.4%.
The Board authorized a share repurchase of up to $5.0 million on June 26, 2026; the company has repurchased 5,112,000 shares for about $1.11 million as of this date.
American Battery Technology reported preliminary, unaudited results for the quarter ended June 30, 2026, with revenue up 5.1% to $8.2 million and gross profit up 86% to $1.3 million from the prior quarter. The company also warned that a federal directive taking effect August 27, 2026 could block most of its foreign black mass sales, which it says make up the majority of total revenue and could have a material adverse effect.
Q4 FY26 revenue of $8.2 million, up 5.1% from $7.8 million in Q3 FY26
Gross profit of $1.3 million, up 86% from $0.7 million in Q3 FY26; cost of goods sold fell 2.8% to $6.9 million
Department of Commerce directive requires U.S. black mass sellers to allocate 100% of sales to U.S. persons, effective August 27, 2026; public comment period open until November 4, 2026
Company has submitted an exception request to BIS; there is no assurance it will be granted
RF Acquisition Corp II shareholders voted on August 19, 2026, at an extraordinary general meeting and approved the Business Combination Proposal, which covers the merger with NYB Holdings Limited and the amalgamation with Nanyang Biologics Pte. Ltd. Holders also submitted preliminary requests to redeem 3,956,323 shares for cash from the trust account, and the company says the closing may not occur and the final redemption figures cannot be determined until closing.
Business Combination Proposal: 6,765,584 votes for, 440,604 against, 0 abstentions, out of 7,206,188 shares present (86.36% of 8,343,765 shares entitled to vote)
Preliminary redemption requests for 3,956,323 RFAC ordinary shares, subject to withdrawal or reversal before closing
Closing remains subject to closing conditions and may not occur; final redemption amounts will be disclosed after closing
Other proposals, including the merger, Nasdaq issuance, incentive plan and adjournment, received the same vote counts
On August 20, 2026, James Hardie agreed to sell its European fiber gypsum and cement-bonded products business, including Fermacell, to a subsidiary of Holcim for €840 million, about $980 million. The company expects about $600 million of the proceeds to repay debt and has also authorized a $250 million share repurchase program. The sale is expected to close in the first half of 2027, and the company plans to wind down its European fiber cement operations, which are not included in the sale.
Buyer is Holcim Westbeteiligungs GmbH, a subsidiary of Holcim Ltd., with Holcim Ltd. as guarantor; price is €840 million, subject to net debt and working capital adjustments
About $600 million of proceeds is expected to repay debt, supporting a target of net leverage below 2.0x by September 30, 2027
Board authorized a share repurchase program of up to $250 million; the company is not obligated to buy any shares
Closing expected in the first half of calendar 2027, subject to antitrust approvals and employee consultations; the Purchaser may owe the Sellers a €15 million termination fee in certain circumstances
Abbott agreed to resolve the Gill lawsuit and necrotizing enterocolitis claims for about 2,000 other infants for an aggregate of approximately $670 million, instead of continuing its appeal or paying about $600 million on the Gill judgment plus interest. The company states the agreements are a compromise and not an admission of liability, but the payment is a sizable cost, and roughly 1,700 lawsuits involving about 12,700 infants remain pending.
Gill case: July 2024 Missouri jury verdict of $495 million, affirmed by the Missouri Court of Appeals in May 2026.
Settlement: aggregate amount of approximately $670 million covering the Gill case and claims for about 2,000 additional infants.
Alternative cited: paying approximately $600 million, the Gill judgment plus accrued interest to date.
Remaining litigation: roughly 1,700 lawsuits involving claims for about 12,700 individual infants.
Edesa Biotech, Inc. priced an underwritten public offering of 3,870,500 common shares and pre-funded warrants for up to 675,000 common shares, each sold with a common share warrant, with gross proceeds expected to be approximately $25.0 million. The company expects net proceeds of approximately $23.1 million, to be used for general corporate purposes, and expects the offering to close on or about August 21, 2026, which adds new shares and warrants that can dilute existing shareholders.
Combined offering price of $5.50 per common share with a warrant, and $5.4999 per pre-funded warrant with a warrant.
Expected net proceeds of approximately $23.1 million; closing expected on or about August 21, 2026.
Warrants have a $7.50 exercise price and expire on the earlier of the 18-month anniversary of issuance or 30 days after public announcement of Phase 2 vitiligo topline data for EB06.
Underwriters hold a 30-day option to buy up to 681,825 additional shares; executive officers and directors agreed to a 90-day lock-up, subject to exceptions.
Evolution Petroleum agreed on August 18, 2026 to sell 3,700,000 common shares at $3.25 per share, and the underwriters exercised their option in full on August 19 for 555,000 more shares. The company received net proceeds of approximately $12.4 million, and the offering closed on August 20, 2026. The company plans to use the proceeds to help fund a previously announced Permian Basin mineral and royalty acquisition, but the offering is not conditioned on that deal closing.
3,700,000 shares priced at $3.25 per share on August 18, 2026; Roth Capital Partners acted as representative of the underwriters.
Underwriters exercised the 30-day option in full on August 19, 2026, for 555,000 additional shares.
Net proceeds of approximately $12.4 million; the offering closed on August 20, 2026.
Proceeds are intended for part of the Permian Basin acquisition price, credit facility borrowings, cash on hand and general corporate purposes; the company cannot assure the acquisition will be completed.
OSI Systems reported fiscal fourth-quarter revenue of $484.1 million, down 4% from a year earlier, while GAAP diluted EPS rose 8% to $3.27. Management attributed the revenue decline to Middle East conflicts that shifted the timing of some deliveries, and said the delays do not reflect order cancellations. The company also introduced fiscal 2027 guidance and its board added 1 million shares to the buyback authorization.
Q4 revenue $484.1 million, down 4%; GAAP diluted EPS $3.27, up 8%; non-GAAP diluted EPS $3.78, up 17%
Fiscal 2026 revenue $1.79 billion, up 4%; GAAP diluted EPS $8.95, up 3%; backlog about $1.9 billion as of June 30, 2026
Fiscal 2027 guidance: revenue $1.875 billion to $1.930 billion; non-GAAP diluted EPS $11.13 to $11.49
Board approved 1 million additional shares for repurchase, bringing total remaining authorization to 1,078,731 shares
BTCS reported second-quarter 2026 results, with total revenue up 14% from the first quarter to $2.4 million and gross profit up 47% to $1.5 million at a 61% margin, driven by its Imperium DeFi business. The company still posted a net loss of $34.9 million, mainly from non-cash digital asset losses, though that was smaller than the $69.1 million loss in the first quarter and the company had net income of $3.9 million in the year-earlier quarter.
Total revenue was $2.4 million for Q2 2026, up 14% from $2.1 million in Q1 2026; DeFi revenue from Imperium rose 48% to $1.5 million.
Gross profit was $1.5 million (61% margin) versus $1.0 million (47% margin) in Q1 2026.
Net loss was $34.9 million for Q2 2026, compared with a net loss of $69.1 million in Q1 2026 and net income of $3.9 million in Q2 2025.
Total debt fell to $50.4 million as of June 30, 2026, from $74.8 million on March 31, 2026, and total assets were $89.3 million.
LSI Industries reported fiscal fourth-quarter 2026 net sales of $234.6 million, up 51% year over year, helped by the Royston Group acquisition, with organic growth of 8%. GAAP net income fell 16% to $6.9 million ($0.18 per diluted share), though adjusted EPS rose to $0.38 from $0.34, and the company declared a $0.05 quarterly dividend.
Q4 net sales $234.6 million, up 51%; Royston contributed $66.9 million; organic sales up 8%
Q4 diluted EPS $0.18 as reported vs. $0.26 a year earlier; adjusted EPS $0.38 vs. $0.34
Fiscal 2026 net sales record $689.4 million, up 20%; GAAP net income $22.6 million vs. $24.4 million
Regular quarterly dividend of $0.05 per share payable September 8, 2026, to holders of record August 31, 2026
Walmart reported second-quarter results for the three months ended July 31, 2026, with revenue of $187.9 billion, up 5.9%, and operating income up 28.8% to $9.4 billion. GAAP diluted earnings per share fell 9.1% to $0.80, a period that included $1.2 billion in other losses, while the company raised its fiscal 2027 adjusted EPS guidance to $2.80 to $2.87.
Q2 GAAP diluted EPS was $0.80, down from $0.88; adjusted EPS was $0.81 after excluding a $0.12 net loss on equity and other investments and a $0.11 net benefit from a tax matter.
Q2 operating income was $9.4 billion, up 28.8%, including the impact of tariff refunds received, partly offset by price investments.
FY27 adjusted EPS guidance is $2.80 to $2.87, up from $2.75 to $2.85 previously; net sales growth guidance is 4.0% to 5.0% in constant currency.
Q3 adjusted EPS is expected to be $0.62 to $0.64, with Q3 net sales growth of 3.0% to 3.75% in constant currency.
Advance Auto Parts reported second-quarter 2026 net sales of $2.0 billion, roughly flat with the prior year, with comparable store sales down 0.5%. Adjusted diluted EPS rose to $1.03 from $0.69, helped by about $0.31 of tariff refunds, and the company reaffirmed most full-year 2026 guidance.
Net sales $2.0 billion vs. $2.0 billion a year earlier; comparable store sales fell 0.5%, with DIY spending weaker than expected in the last four weeks of the quarter
Diluted EPS $0.90 vs. $0.25 a year earlier; adjusted diluted EPS $1.03 vs. $0.69, with tariff refunds contributing about $0.31
Full-year 2026 net sales guidance of $8,485 million to $8,575 million reaffirmed; adjusted diluted EPS guidance revised for higher pre-tax interest income
Year-to-date free cash flow of $120 million vs. negative $201 million a year earlier; net leverage 2.1x vs. 2.4x in Q1 2026
InnSuites Hospitality Trust agreed to convert the $3,000,000 balance on its revolving credit line with affiliate Rare Earth Financial, LLC into 1,829,268 shares of common stock, priced at $1.64 per share. The conversion adds shares to the count and removes the debt owed to this affiliate. The company also reported a record July 2026 revenue total and first-half fiscal 2027 revenue above $4.1 million.
Debt Conversion Agreement executed August 19, 2026 converts $3,000,000 principal owed to Rare Earth Financial, LLC into IHT common stock, with $0 accrued interest and $0 other amounts.
1,829,268 shares to be issued at $1.64 per share, the closing price on August 18, 2026 on the NYSE American, as agreed by the Board of Trustees and NYSE American.
Two hotels recorded a July revenue total of $597,323, the highest July total ever for the two hotels combined.
IHT total revenues for the fiscal first half of 2027 (February 1 to July 31, 2026) exceeded $4.1 million; the company continues to seek a reverse merger partner.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.